GSK 5536522
Alternative Names: Flu mRNA - GSK; flu pandemic messenger RNA (mRNA) vaccine - GlaxoSmithKline; Flu Pandemic mRNA - GSK; GSK-5536522; H5N1 influenza vaccine - GlaxoSmithKline; H5N1 m-RNA vaccine - GlaxoSmithKline; Pandemic H5N1 influenza virus vaccineLatest Information Update: 21 Jul 2026
At a glance
- Originator GSK
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H5N1 subtype
Most Recent Events
- 21 Jul 2026 Discontinued - Phase-I/II for Influenza A virus H5N1 subtype (Prevention) in USA (IM) (GSK pipeline; July 2026)
- 13 Jan 2026 GlaxoSmithKline completes a phase-I/II trial in Influenza A virus H5N1 subtype (Prevention) in USA (IM) (NCT06382311)
- 18 Apr 2024 Phase-I/II clinical trials in Influenza A virus H5N1 subtype(Prevention) in USA (IM) (NCT06382311)